|A Clinically-Proven Effective
for the Treatment goal of Type 2 Diabetes!
Apart from having promising available
human data, we are sponsoring a
CRO-monitored clinical trial to.....
Read more >>>
Phase 2a Clinical Trial Approved in India
(6th April 2018)
Patient recruitment is anticipated in June 2018.
CEO presented at The Microbiome R&D
and Business Collaboration Congress:
Asia (6th March 2018)
Presented latest insight into our technology at
Our patent granted in Russia
(25th January 2018)
Russian Patent Office has granted our
GlyConMedics is planning to provide a simple, natural and cost-effective solution for one of the world's fastest growing disease. We have discovered
and patented a Food for Special Medical Purpose (Medical Food) for the treatment of type 2 diabetes mellitus (T2DM), comprising a specific
Prebiotic product (designated OZ101) that synergizes with the sulfonylurea anti-diabetes drugs. While intake of sulfonylurea exclusively controls blood
glucose levels, adjunctive intake of our patented prebiotic OZ101 results in amelioration of major side effects of sulfonylurea (i.e. weight gain and
hypoglycemia) and extends duration and strength of its effectiveness......Read More
The company has received two merit-based government grants to conduct commercial and regulatory due diligence and to complete a proof-of-concept